LYFE Capital
济峰资本
elsewhere's corpus has no dedicated profile of LYFE Capital (济峰资本) — no founding story, team, or fund-size details. What does show up is a consistent deal footprint: LYFE appears repeatedly as a co-investor in Chinese life sciences rounds alongside Gaorong Ventures, Qiming Venture Partners and others. It co-led (with Gaorong) the near-RMB-200M Pre-IPO round of cell-therapy company ImmuPeak (易慕峰生物) in early 2026 , followed in Zenitar's ~RMB 400M Series B+ led by Qiming in August 2025 , and participated in Biointron's ~RMB 500M Series B back in 2022 , nucleic-acid drug maker Onto's $50M+ Series A in 2024 , and a record 330M-yuan angel round for invasive BCI startup Initiative Tech in 2026 . On that evidence LYFE reads as a healthcare-focused fund active across innovative drugs, CRO, cell therapy and frontier medtech — but anything beyond that deal trail isn't covered in elsewhere's material.
AI-generated — may contain errors, please verify.
Coverage
Dalton Venture Backs Invasive BCI, Active Technologies' 330 Million Yuan Angel Round Sets New Domestic Record for Brain-Computer Interface Funding | Dalton News
On August 3, **Shanghai Initiative Technology Co., Ltd. (hereinafter referred to as "Initiative Technology") announced the completion of a 330 million RMB angel funding round, setting a new record for angel-round financing in China's brain-computer interface sector. This round was led by CASSTAR, with co-investment from Dalton Venture, Legend Star, Unity Ventures, Inno Angel Fund, BGI Songhe Bio Fund, LYFE Capital, and Jiadao Capital**. The proceeds will be mainly used for facility expansion, equipment upgrades, and clinical trial advancement.
Invasive brain-computer interface startup Initiative Tech raises 330 million yuan in record China BCI angel round | Unity Ventures portfolio newcomer
The domestic invasive brain-computer interface company with the most comprehensive product line
Rongbao | Karl Dynamics, Aerofugia, StarsComm, and ImmuPeak Kick Off the Year with Major Funding Rounds
Leading the industry into a new era.
ImmuPharm Raises Nearly RMB 200 Million in Pre-IPO Round Co-Led by Gaorong Ventures, Building Dual Engine in Solid Tumors and In Vivo CAR-T
Bringing long-term survival benefits to cancer patients worldwide.
5Y News | Zai Ling Bio Completes Nearly RMB 400 Million Series B+ Round
Accelerating the buildout of an innovative drug pipeline built on differentiated molecular scaffolds and novel targets, with a commitment to addressing unmet clinical needs.
Zenitar Closes Nearly RMB 400 Million Series B+ Round, Multiple Global First-in-Class Drugs Enter Pivotal Clinical Trials
Structural Biology and AI-Driven Innovative Drug Discovery and Development
Zenitar Raises Nearly 400 Million Yuan in B+ Round Led by Qiming Venture Partners
Zenitar is a structure-based biology and AI-driven innovative drug R&D company, focused on unmet clinical needs in major therapeutic areas including oncology, autoimmune diseases, inflammation, and neurological disorders. The company is dedicated to discovering, developing, and commercializing first-in-class and best-in-class innovative medicines.
Rongbao | Major Acquisition in Innovative Drugs; Laser Chips, Quantum Computing, and Global Payment Platform Secure New Funding
"Every step forward feels like a bloom."
Onto Innovation Completes Over $50 Million Series A Financing to Accelerate Deep Pipeline Expansion in Nucleic Acid Drugs
Focused on drug development based on antisense oligonucleotide technology.
Robotics, SaaS, and innovative drug sectors close new funding rounds; chips and medical devices unveil major new products | Rongbao · August
Differentiated innovation and global opportunities.
Antibody discovery CRO **Baiying Biotech** closes nearly RMB 500 million Series B round
Specializing in antibody discovery CRO services to accelerate antibody drug development.
